[管理者用] 最新ニュース(タブ)
サブ-ナビゲーション
  • information
  • News
  • Corporate Guide
  • Business
  • Investor Relations
  • Sustainability
  • Contact Us

[管理者用] 最新ニュース(タブ)

  • What’s new
  • Press Release
  • Investor Relations
  • Information
  • 2026/02/13 (Summary) Notice Concerning Expression of Opinion in Support of Tender Offer for Company Shares by Takara Holdings, and Recommendation to Tender Share pdf （254KB）
  • 2026/02/13 Consolidated Financial Results for the Nine Months Ended December 31, 2025 (Under Japanese GAAP) pdf （485KB）
  • 2026/02/06 Waskyra™, a Gene Therapy Manufactured Using RetroNectin®, Receives U.S. and EU Marketing Authorization Approvals
  • 2025/11/12 [Correction] Notice Concerning Revisions to Notice Concerning Revisions to the Financial Results Forecasts and Dividend Forecasts (No dividends) and P pdf （161KB）
  • 2025/11/11 Notice Concerning Revisions to the Financial Results Forecasts and Dividend Forecasts (No dividends) and Partial Return of Executive Remuneration pdf （141KB）
  • Read More
  • 2026/02/06 Waskyra™, a Gene Therapy Manufactured Using RetroNectin®, Receives U.S. and EU Marketing Authorization Approvals
  • 2025/09/16 Completion of Clinical Trial Notification Process in Japan for Confirmatory Study of NY-ESO-1・siTCR™ Gene Therapy
  • 2025/09/12 Announcement of “Takara Bio Group Long-Term Vision 2050”
  • 2025/06/04 Redesign of the Regulatory Strategy for NY-ESO-1・siTCR™ Gene Therapy in Japan
  • 2024/06/27 Takara Bio announces the business partnership with Gap Junction Therapeutics to develop AAV gene therapy for hereditary hearing loss
  • Read More
  • 2026/02/13 (Summary) Notice Concerning Expression of Opinion in Support of Tender Offer for Company Shares by Takara Holdings, and Recommendation to Tender Share pdf （254KB）
  • 2026/02/13 Consolidated Financial Results for the Nine Months Ended December 31, 2025 (Under Japanese GAAP) pdf （485KB）
  • 2025/11/12 [Correction] Notice Concerning Revisions to Notice Concerning Revisions to the Financial Results Forecasts and Dividend Forecasts (No dividends) and P pdf （161KB）
  • 2025/11/11 Notice Concerning Revisions to the Financial Results Forecasts and Dividend Forecasts (No dividends) and Partial Return of Executive Remuneration pdf （141KB）
  • 2025/11/11 Consolidated Financial Results for the Six Months Ended September 30, 2025 pdf （310KB）
  • Read More
  • 2024/05/02 Takara Bio to Present Advances in Gene and Cell Research at ASGCT 2024
  • Read More

PAGETOP
PAGETOP
  • CLOSE
  • MENU

サイト内検索

  • footer-content
  • menu
  • JA
  • EN
  • contact
  • gnavi-box